Novo Nordisk A/S (Novo Nordisk A/S) Other Long Term Assets

: $3,191 Mil (As of Dec. 2023)

View and export this data going back to 1981. Start your Free Trial

Novo Nordisk A/S's other long-term assets for the quarter that ended in Dec. 2023 was $3,191 Mil.

Novo Nordisk A/S's quarterly other long-term assets increased from Jun. 2023 ($2,321 Mil) to Sep. 2023 ($2,754 Mil) and increased from Sep. 2023 ($2,754 Mil) to Dec. 2023 ($3,191 Mil).

Novo Nordisk A/S's annual other long-term assets increased from Dec. 2021 ($1,358 Mil) to Dec. 2022 ($2,009 Mil) and increased from Dec. 2022 ($2,009 Mil) to Dec. 2023 ($3,191 Mil).

Novo Nordisk A/S Other Long Term Assets Historical Data

The historical data trend for Novo Nordisk A/S's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long Term Assets

738.07

1,069.27

1,358.31

2,009.14

3,191.02

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Long Term Assets																2,009.14	2,066.69	2,321.05	2,753.98	3,191.02

Novo Nordisk A/S Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

NONOF:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.